FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue. See

Instruction 1(b).
(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

	OMB	APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Kotzin Brian L.			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X_ Director 10% Owner						
(Last) (First) (Middle) RIGEL PHARMACEUTIALS, INC., 1180 VETERANS BOULEVARD				3. Date of Earliest Transaction (Month/Day/Year) 05/17/2018					_	Officer (give	e title below)	Otl	er (specify below)		
(Street) SOUTH SAN FRANCISCO, CA 94080			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(Cit		(State)	(Zip)			Tabl	e I - No	n-Deriv	ative Securition	es Acquire	ed, Disposed	of, or Bene	ficially Owr	ed	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea					if Coo (Ins	(Instr. 8)				5. Amount of Securities I Owned Following Report Transaction(s)			Ownership of I Form: Ber	eneficial	
				(Month	/Day/Ye		Code	V A	(A) or (D)	Price (Ir	or Indirect (I)		or Indirect (I	wnership nstr. 4)	
							1	ersons	who respon	ia to the (collection (or intormat	ion contai	1ea SEC 14	1/4 (9-02)
							cquirec	lisplays 1, Dispo	orm are not r s a currently sed of, or Beno evertible secur	valid OM eficially O	B control n		e form		
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	ts, calls, 5. N tion of I Sec Acc or I of (fumber Derivation urities uired (Dispose D) tr. 3, 4,	cquirecents, opti	displays d, Dispo ions, cor oate Exer	sed of, or Benovertible secur reisable and	valid OM eficially O	wned amount clying s	umber.	9. Number	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	ts, calls, 5. N tion of I Sec or I of ((Ins and	fumber Derivati urities uired (Dispose D) tr. 3, 4,	ccquirectors, option of the control	Iisplays I, Dispo ions, cor Date Exer iration I onth/Day	s a currently sed of, or Benevertible secur cisable and Date //Year) Expiration	reficially Onities) 7. Title a of Under Securities	wned amount clying s	8. Price of Derivative Security	9. Number Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	of Indirect Beneficial Ownership (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Kotzin Brian L. RIGEL PHARMACEUTIALS, INC. 1180 VETERANS BOULEVARD SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	05/18/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.